2024
Blood Magnesium Level and Risk of Hepatocellular Carcinoma in a Prospective Liver Cirrhosis Cohort.
Zhang X, Zhao L, Dai Q, Hou T, Danford C, Lai M, Zhang X. Blood Magnesium Level and Risk of Hepatocellular Carcinoma in a Prospective Liver Cirrhosis Cohort. Cancer Epidemiology Biomarkers & Prevention 2024, 33: 1368-1374. PMID: 39037332, PMCID: PMC11579948, DOI: 10.1158/1055-9965.epi-24-0327.Peer-Reviewed Original ResearchConceptsRisk of hepatocellular carcinomaBlood magnesium levelsHepatocellular carcinomaLiver cirrhosisMagnesium levelsAssociated with higher HCC riskHigh risk of hepatocellular carcinomaHazard ratioMedian follow-up periodEnd-stage liver disease scoreIdentification of high-risk patientsHigh riskHigher HCC riskHigher magnesium intakeIncident hepatocellular carcinomaHigh-risk patientsLiver Disease scoreFollow-up periodCox proportional hazards modelsBody mass indexConfidence intervalsAlcoholic liver diseaseClassification of Diseases codesProportional hazards modelInternational Classification of Diseases codesWaiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study
Vitale A, Trapani S, Russo F, Miele L, Baroni G, Marchesini G, Burra P, Ottoveggio M, Romagnoli R, Martini S, De Simone P, Carrai P, Cescon M, Morelli M, De Carlis L, Belli L, Gruttadauria S, Volpes R, Colledan M, Fagiuoli S, Di Benedetto F, De Maria N, Rossi G, Caccamo L, Donato F, Vennarecci G, Di Costanzo G, Vivarelli M, Carraro A, Sacerdoti D, Ettorre G, Giannelli V, Agnes S, Gasbarrini A, Rossi M, Corradini S, Mazzaferro V, Bhoori S, Manzia T, Lenci I, Zamboni F, Mameli L, Baccarani U, Toniutto P, Lupo L, Tandoi F, Rendina M, Andorno E, Giannini E, Spada M, Billato I, Marchini A, Romano P, Brancaccio G, D’Amico F, Ricci A, Cardillo M, Cillo U, del Fegato . A, . S, Trapianti C. Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study. JHEP Reports 2024, 6: 101147. PMID: 39282226, PMCID: PMC11399673, DOI: 10.1016/j.jhepr.2024.101147.Peer-Reviewed Original ResearchSurvival benefit of patientsTransplant survival benefitHepatocellular carcinomaLiver transplantationLiver diseaseIncreased waitlist mortalityPatient survivalBenefit of patientsSteatotic liver diseaseEnd-stage chronic liver diseaseAbstractText Label="Background &Waiting listImprove patient survivalWaitlist mortalityLiver transplant indicationsChronic liver diseaseAlcoholic liver diseaseRisk of deathWaiting list mortalityAbstractText Label="ImpactPrognostic featuresTransplant eligibility criteriaSurvival benefitTransplant indicationAdult patients
2023
Inferior outcomes of liver transplantation for hepatocellular carcinoma during early-COVID-19 pandemic in the United States
Lee I, Okumura K, Misawa R, Sogawa H, Veillette G, John D, Diflo T, Nishida S, Dhand A. Inferior outcomes of liver transplantation for hepatocellular carcinoma during early-COVID-19 pandemic in the United States. World Journal Of Hepatology 2023, 15: 554-563. PMID: 37206654, PMCID: PMC10190691, DOI: 10.4254/wjh.v15.i4.554.Peer-Reviewed Original ResearchLiver transplantationHepatocellular carcinomaUnited Network for Organ SharingAlcoholic liver diseaseGraft survivalPathological characteristics of hepatocellular carcinomaMultivariate Cox hazard regression analysisCox hazard regression analysisCharacteristics of hepatocellular carcinomaOutcome of liver transplantationDiagnosis of non-alcoholic steatohepatitisOutcomes of LTSurvival of liver transplantationUnited StatesPost-transplant mortalityField of transplantationDonor risk indexNon-alcoholic steatohepatitisLT recipientsRecipient agePostoperative outcomesInferior outcomesAdult LTRoutine medical careVascular invasionAlcoholic foamy degeneration: an unusual presentation of the alcoholic liver disease diagnosed on autopsy
Joshi R, Parkhi M, Gupta A, Susngi T, Kumar A, Dhibar D, Mitra S. Alcoholic foamy degeneration: an unusual presentation of the alcoholic liver disease diagnosed on autopsy. Autopsy And Case Reports 2023, 13: e2023446. PMID: 38034523, PMCID: PMC10688259, DOI: 10.4322/acr.2023.446.Peer-Reviewed Original ResearchAlcoholic foamy degenerationAlcoholic liver diseasePresentation of alcoholic liver diseaseLiver diseaseUnusual presentationAlcohol abstinenceAlcoholic hepatitisDiabetic menHistological findingsFoamy degenerationMidzonal regionInjury mechanismAutopsyDiseasePresentationBiopsyPrognosisFibrosisHepatitisPatientsInflammation
2022
Inferior Liver Transplant Outcomes during early COVID-19 pandemic in United States
Okumura K, Nishida S, Sogawa H, Veillette G, Bodin R, Wolf D, Dhand A. Inferior Liver Transplant Outcomes during early COVID-19 pandemic in United States. Journal Of Liver Transplantation 2022, 7: 100099. PMID: 38013989, PMCID: PMC9110062, DOI: 10.1016/j.liver.2022.100099.Peer-Reviewed Original ResearchLiver transplantationAlcoholic liver diseaseRejection episodesTransplant outcomesLiver diseaseRate of rejection episodesMultivariate Cox regression analysisPrimary diagnosisUnited Network for Organ Sharing databaseAdult LT recipientsHigher donor risk indexSolid organ transplantationPost-transplant graft survivalCox regression analysisLiver transplant outcomesDonor risk indexGraft/patient survivalGraft survivalPost-transplantGraft failureMELD scoreSharing databaseRisk factorsTransplantationCharacteristics of donorsLiver metabolomics identifies bile acid profile changes at early stages of alcoholic liver disease in mice
Charkoftaki G, Tan WY, Berrios-Carcamo P, Orlicky DJ, Golla JP, Garcia-Milian R, Aalizadeh R, Thomaidis NS, Thompson DC, Vasiliou V. Liver metabolomics identifies bile acid profile changes at early stages of alcoholic liver disease in mice. Chemico-Biological Interactions 2022, 360: 109931. PMID: 35429548, PMCID: PMC9364420, DOI: 10.1016/j.cbi.2022.109931.Peer-Reviewed Original ResearchConceptsAlcoholic liver diseaseEthanol-consuming miceAlcohol consumptionLiver diseaseDevelopment of ALDBile acid changesChronic alcohol drinkingChronic alcohol consumptionLieber-DeCarli dietAlcohol-induced alterationsGlobal healthcare problemBile acid biosynthesisAlcohol drinkingLiver histopathologyTissue injuryClinical consequencesUntargeted metabolomics analysisEarly stagesComplex pathologyMinimal changesUntargeted metabolomics approachEarly onsetHealthcare problemMiceLiver
2020
The lymphatic system in alcohol-associated liver disease
Kondo R, Iwakiri Y. The lymphatic system in alcohol-associated liver disease. Clinical And Molecular Hepatology 2020, 26: 633-638. PMID: 32951411, PMCID: PMC7641555, DOI: 10.3350/cmh.2020.0179.BooksConceptsAlcoholic liver diseaseLymphatic systemLiver diseaseTreatment of ALDAlcohol-associated liver diseaseAlcohol-related diseasesEffects of alcoholHepatic lymphaticsFluid balanceCell surveillanceTherapeutic potentialImmune cell surveillanceDiseaseInterstitial fluid balanceReview articlePathogenesisLymphaticsComprehensive characterization of hepatocyte-derived extracellular vesicles identifies direct miRNA-based regulation of hepatic stellate cells and DAMP-based hepatic macrophage IL-1β and IL-17 upregulation in alcoholic hepatitis mice
Eguchi A, Yan R, Pan S, Wu R, Kim J, Chen Y, Ansong C, Smith R, Tempaku M, Ohno-Machado L, Takei Y, Feldstein A, Tsukamoto H. Comprehensive characterization of hepatocyte-derived extracellular vesicles identifies direct miRNA-based regulation of hepatic stellate cells and DAMP-based hepatic macrophage IL-1β and IL-17 upregulation in alcoholic hepatitis mice. Journal Of Molecular Medicine 2020, 98: 1021-1034. PMID: 32556367, PMCID: PMC7810220, DOI: 10.1007/s00109-020-01926-7.Peer-Reviewed Original ResearchConceptsHepatic stellate cellsAlcoholic liver diseaseAlcoholic hepatitisAH miceIL-1βHepatic macrophagesStellate cellsExtracellular vesiclesPrimary hepatic stellate cellsIL-17 upregulationIL-17 productionUpregulated IL-1βHepatocyte-derived extracellular vesiclesNovel murine modelTLR9-dependent mannerMacrophage IL-1βHepatitis miceIL-17Liver diseaseControl miceCytokine productionLiver pathologyLiver fibrogenesisMurine modelΑ-SMARecent advances of sterile inflammation and inter-organ cross-talk in alcoholic liver disease
Shim Y, Jeong W. Recent advances of sterile inflammation and inter-organ cross-talk in alcoholic liver disease. Experimental & Molecular Medicine 2020, 52: 772-780. PMID: 32457490, PMCID: PMC7272465, DOI: 10.1038/s12276-020-0438-5.Peer-Reviewed Original ResearchConceptsDamage-associated molecular patternsAlcoholic liver diseaseNon-parenchymal cellsSterile inflammationLiver diseaseGeneration of damage-associated molecular patternsCellular pattern recognition receptorsMultiple pro-inflammatory cytokinesSpectrum of alcoholic liver diseaseToll-like receptorsPro-inflammatory cytokinesHepatic stellate cellsAlcoholic liver injuryPattern recognition receptorsDouble-stranded RNACross-talkInter-organ cross-talkAlcohol-mediatedBone marrowImmune cellsInduce de novo lipogenesisMitochondrial double-stranded RNALiver injuryKupffer cellsPortal circulationHedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells
Gupta V, Gupta I, Park J, Bram Y, Schwartz RE. Hedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells. Gastroenterology 2020, 159: 624-638.e9. PMID: 32289375, PMCID: PMC8204800, DOI: 10.1053/j.gastro.2020.03.075.Peer-Reviewed Original ResearchConceptsCholestatic injuryStellate cellsLiver tissueStromal cellsLiver diseaseBile ductBiliary treePortal tractsMesenchymal cellsPrimary sclerosing cholangitisAlcoholic liver diseaseEpithelial cellsMyofibroblast phenotypeQuantitative reverse transcription polymerase chain reactionBile duct ligationReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionCanals of HeringControl liver tissueHedgehog signalingSclerosing cholangitisHepatic injuryHepatocellular injuryNonalcoholic steatohepatitisPortal fibroblastsNIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease
Li Y, Chen M, Zhou Y, Tang C, Zhang W, Zhong Y, Chen Y, Zhou H, Sheng L. NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease. Theranostics 2020, 10: 3579-3593. PMID: 32206109, PMCID: PMC7069072, DOI: 10.7150/thno.40149.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsEthanolFatty AcidsFatty LiverHepatocytesInflammationLiver Diseases, AlcoholicMaleMAP Kinase Kinase 1MAP Kinase Kinase 2MiceMice, Inbred C57BLMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Oxidation-ReductionPhosphorylationPPAR alphaProtein Serine-Threonine KinasesSignal TransductionConceptsAlcoholic liver diseaseFatty acid oxidationAlcoholic steatosisHepatic fatty acid oxidationHepatocyte-specific deletionHepatic steatosisLiver diseasePPARα agonistAcid oxidationBinge ethanol feedingMain pathological featuresHepatic lipid accumulationEthanol-fed miceRegulation of PPARαRole of NIKALD therapyInflammatory cytokinesPathological featuresUnderlying pathogenesisPharmacological interventionsSteatosisEthanol feedingInflammationPharmacological inhibitionPPARαThe Role of Bile Acid‐Mediated Inflammation in Cholestatic Liver Injury
Cai S, Li M, Boyer J. The Role of Bile Acid‐Mediated Inflammation in Cholestatic Liver Injury. 2020, 728-736. DOI: 10.1002/9781119436812.ch56.Peer-Reviewed Original ResearchCholestatic liver injuryBile acidsLiver injuryProinflammatory mediatorsInflammatory responseCauses of cholestasisAlcoholic liver diseasePrimary biliary cholangitisConjugated bile acidsEffects of drugsHepatic infiltrationBile acid transporterLiver transplantationViral hepatitisBiliary cholangitisBiliary cirrhosisMetabolic syndromeDuct obstructionLiver diseaseImmune cellsNeutrophil activationPathophysiological levelsCholangitisInflammationInjury
2019
The decreasing predictive power of MELD in an era of changing etiology of liver disease
Godfrey EL, Malik TH, Lai JC, Mindikoglu AL, Galván NTN, Cotton RT, O'Mahony CA, Goss JA, Rana A. The decreasing predictive power of MELD in an era of changing etiology of liver disease. American Journal Of Transplantation 2019, 19: 3299-3307. PMID: 31394020, DOI: 10.1111/ajt.15559.Peer-Reviewed Original ResearchConceptsMELD scoreLiver diseaseNon-alcoholic fatty liver diseaseHCV-positive patientsHCV-positive statusLab-MELD scoreAlcoholic liver diseaseFatty liver diseaseBest supportive therapyDe-identified dataLiver transplantLiver transplantationMELD eraFailure etiologyWaitlist deathsSupportive therapyUnited NetworkEtiology of diseaseOrgan SharingConcordance statisticDiseaseMortalityEtiologyMELDPatientsGlutamate Signaling in Hepatic Stellate Cells Drives Alcoholic Steatosis
Choi W, Kim H, Kim M, Cinar R, Yi H, Eun H, Kim S, Choi Y, Lee Y, Kim S, Seo W, Lee J, Shim Y, Kim Y, Yang K, Ryu T, Hwang J, Lee C, Choi H, Gao B, Kim W, Kim S, Kunos G, Jeong W. Glutamate Signaling in Hepatic Stellate Cells Drives Alcoholic Steatosis. Cell Metabolism 2019, 30: 877-889.e7. PMID: 31474565, PMCID: PMC6834910, DOI: 10.1016/j.cmet.2019.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmino Acid Transport System y+AnimalsArachidonic AcidsEndocannabinoidsFatty Liver, AlcoholicFemaleGlutamic AcidGlyceridesHEK293 CellsHep G2 CellsHepatic Stellate CellsHepatocytesHumansLipogenesisMaleMiceMice, Inbred C57BLMice, KnockoutMiddle AgedReceptor, Cannabinoid, CB1Receptor, Metabotropic Glutamate 5Signal TransductionTransfectionConceptsAlcoholic liver diseaseExpression of metabotropic glutamate receptor 5Pharmacological inhibition of mGluR5Metabotropic glutamate receptor 5Alcoholic steatosisCannabinoid receptor 1Glutamate receptor 5Inhibition of mGluR5Extracellular glutamate levelsGlutamate signalingGlutamate levelsHepatic stellate cellsMGluR5Receptor 5Receptor 1Liver diseaseMetabolic synapsePharmacological inhibitionStellate cellsCystine uptakeCompensatory increaseCysteine deficiencyGlutathione depletionSteatosisMiceVitamin E in Nonalcoholic Fatty Liver Disease
Banini B, Sanyal A. Vitamin E in Nonalcoholic Fatty Liver Disease. Nutrition And Health 2019, 311-323. DOI: 10.1007/978-3-030-05315-4_23.ChaptersNonalcoholic fatty liver diseaseVitamin E supplementationChronic liver diseaseFatty liver diseaseNonalcoholic steatohepatitisLiver diseaseE supplementationVitamin ESubtype of NAFLDAnnual direct medical costsChronic viral hepatitisAlcoholic liver diseaseClinical practice guidelinesDirect medical costsLong-term useNAFLD patientsLabel treatmentViral hepatitisPharmacological therapyComplex pathogenesisHistological featuresLiver fibrosisClinical trialsLeading causeClinical studiesLiver Transplantation for Alcoholic Liver Disease An Update
Godfrey EL, Stribling R, Rana A. Liver Transplantation for Alcoholic Liver Disease An Update. Clinics In Liver Disease 2019, 23: 127-139. PMID: 30454827, DOI: 10.1016/j.cld.2018.09.007.Peer-Reviewed Original ResearchConceptsAlcoholic liver diseaseLiver diseaseAbstinence periodBetter long-term outcomesLiver disease burdenSevere alcoholic hepatitisOverall favorable outcomeLong-term outcomesAlcohol use treatmentUnique health concernsMinimum abstinence periodPosttransplantation riskAlcoholic hepatitisLiver transplantationMetabolic complicationsEarly transplantationDisease burdenFavorable outcomeBetter outcomesHealth concernUse treatmentTransplantationOutcomesDiseaseSelection criteria
2018
β-Hydroxybutyrate protects from alcohol-induced liver injury via a Hcar2-cAMP dependent pathway
Chen Y, Ouyang X, Hoque R, Garcia-Martinez I, Yousaf MN, Tonack S, Offermanns S, Dubuquoy L, Louvet A, Mathurin P, Massey V, Schnabl B, Bataller R, Mehal WZ. β-Hydroxybutyrate protects from alcohol-induced liver injury via a Hcar2-cAMP dependent pathway. Journal Of Hepatology 2018, 69: 687-696. PMID: 29705237, PMCID: PMC6098974, DOI: 10.1016/j.jhep.2018.04.004.Peer-Reviewed Original ResearchConceptsAlcohol-induced liver injuryAlcoholic hepatitisAlanine aminotransferase levelsLiver injuryNeutrophil influxAminotransferase levelsΒ-hydroxybutyrateDevelopment of AHPlasma alanine aminotransferase levelsGreater neutrophil influxExcess alcohol intakeAlcoholic liver diseaseLife-threatening conditionExcess alcohol consumptionDependent pathwayHigher plasma alanine aminotransferase levelsIntrahepatic macrophagesLiver inflammationLiver diseaseAlcohol intakeHepatoprotective roleReduced steatosisM2 phenotypeTherapeutic effectHepatitisText Messaging to Reduce Alcohol Relapse in Prelisting Liver Transplant Candidates: A Pilot Feasibility Study
DeMartini KS, Schilsky ML, Palmer A, Fehon DC, Zimbrean P, O'Malley SS, Lee HB, Toll BA. Text Messaging to Reduce Alcohol Relapse in Prelisting Liver Transplant Candidates: A Pilot Feasibility Study. Alcohol Clinical And Experimental Research 2018, 42: 761-769. PMID: 29498753, PMCID: PMC6438371, DOI: 10.1111/acer.13603.Peer-Reviewed Original ResearchConceptsAlcoholic liver diseaseLiver transplant candidatesLiver transplant patientsStandard careEfficacy outcomesTransplant patientsTransplant candidatesFeasibility outcomesTM participantsAlcohol interventionsClinical efficacy outcomesLiver transplantation programPreliminary efficacy outcomesPrimary feasibility outcomePilot feasibility trialPilot feasibility studyRelapse prevention interventionsBetter treatment outcomesLiver diseaseFeasibility trialUnited NetworkTransplantation programIntervention satisfactionTreatment outcomesAlcohol relapseThe rs626283 Variant in the MBOAT7 Gene is Associated with Insulin Resistance and Fatty Liver in Caucasian Obese Youth
Umano GR, Caprio S, Di Sessa A, Chalasani N, Dykas DJ, Pierpont B, Bale AE, Santoro N. The rs626283 Variant in the MBOAT7 Gene is Associated with Insulin Resistance and Fatty Liver in Caucasian Obese Youth. The American Journal Of Gastroenterology 2018, 113: 376. PMID: 29485130, PMCID: PMC12136689, DOI: 10.1038/ajg.2018.1.Peer-Reviewed Original ResearchMeSH KeywordsAcyltransferasesAdolescentAllelesBlack or African AmericanChildFemaleGenetic Predisposition to DiseaseGenotypeGlucose Tolerance TestHispanic or LatinoHumansInsulin ResistanceLiverMagnetic Resonance ImagingMaleMembrane ProteinsNon-alcoholic Fatty Liver DiseasePediatric ObesityPolymorphism, Single NucleotideWhite PeopleConceptsCaucasian obese childrenMBOAT7 geneObese childrenLiver diseaseHepatic steatosisInsulin resistanceInsulin sensitivityAlcoholic fatty liver diseaseBody mass index z-scoreOral glucose tolerance testWhole-body insulin sensitivityAlcoholic liver diseaseFatty liver diseaseCurve of glucoseGlucose tolerance testIndex z-scoreMagnetic resonance imagingFatty liverPNPLA3 rs738409Liver damageTolerance testLeading causeMultiethnic cohortObese youthGlucose metabolism
2017
An endoplasmic reticulum protein, Nogo‐B, facilitates alcoholic liver disease through regulation of kupffer cell polarization
Park J, Shao M, Kim MY, Baik SK, Cho MY, Utsumi T, Satoh A, Ouyang X, Chung C, Iwakiri Y. An endoplasmic reticulum protein, Nogo‐B, facilitates alcoholic liver disease through regulation of kupffer cell polarization. Hepatology 2017, 65: 1720-1734. PMID: 28090670, PMCID: PMC5397326, DOI: 10.1002/hep.29051.Peer-Reviewed Original ResearchConceptsAlcoholic liver diseasePositive Kupffer cellsKupffer cellsLiver injuryALD patientsLiver diseaseM1 polarizationKO miceM2 polarizationLieber-DeCarli ethanol liquid dietDisease severityM1/M2 polarizationKupffer cell polarizationEthanol liquid dietHepatic triglyceride levelsM2 macrophage polarizationHigher hepatic triglyceride levelsChronic ethanol feedingNew therapeutic targetsER stressAbsence of NogoM2 statusWT miceM1 activationTriglyceride levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply